drugset / Trial / NCT00740610
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic Steatohepatitis (also known as NASH).
Timeline
- Start
- 2008-08
- Primary completion
- 2009-08
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIVOCASAN | Small molecule | 1 mg | Oral |
| Subject | NIVOCASAN | Small molecule | 5 mg | Oral |
| Subject | NIVOCASAN | Small molecule | 10 mg | Oral |
| Subject | NIVOCASAN | Small molecule | 40 mg | Oral |